2 assets in Granulocytic Sarcoma

Therapeutic assets addressing Granulocytic Sarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Metformin Granulocytic Sarcoma	Wake Forest University Health Sciences	P2	CCC (53)
Devimistat Granulocytic Sarcoma	Wake Forest University Health Sciences	P2	CCC (51)